Effects of iron-depletion on cell cycle progression in normal human T lymphocytes: Selective inhibition of the appearance of the cyclin A- associated component of the p33(cdk2) kinase

J. J. Lucas, A. Szepesi, J. Domenico, K. Takase, A. Tordai, N. Terada, E. W. Gelfand

Research output: Contribution to journalArticle

53 Citations (Scopus)


Iron removal by the chelating-agent deferoxamine (DFO) arrests cell cycle progression of activated human T cells in late G1 phase, before the G1/S border. The effects of the drug on molecules that regulate progression through the cell cycle were defined. DFO (10 μmol/L) inhibited induction of transcription of the cdc2 gene, but had no effect on accumulation of cdk2, cdk4, or interleukin (IL)-2 transcripts. No detectable p34(cdc2) protein accumulated, but synthesis of the p33(cdk2) protein was begun. It accumulated to normal levels during the first 20 to 30 hours of incubation in the presence of DFO. Furthermore, p33(cdk2) was activated as an H1 histone kinase. As active p33(cdk2) primarily represents complexes of the p33 protein with cyclin E or cyclin A, the effects of DFO on these cyclins were examined. Although the induction of synthesis and early accumulation of cyclin E and cyclin E-associated kinase activity appeared normal, the appearance of cyclin A and cyclin A-associated kinase activity were inhibited by DFO. However, the production of cyclin A mRNA appeared to be normal in the presence of DFO. A major effect of DFO in blocking cell cycle progression may be mediated through inhibition of the appearance of cyclin A protein and, therefore, a major component of p33(cdk2) activity. The results also indicate that the p33(cdk2)/cyclin E activity produced in the presence of DFO was not sufficient for completion of the G1 phase of the cell cycle.

Original languageEnglish
Pages (from-to)2268-2280
Number of pages13
Issue number6
Publication statusPublished - Sep 18 1995


ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this